Form 4 for XENE Xenon Pharmaceuticals Inc.
Accepted 2023-12-20 00:00:00 ET · period of report 2023-12-19 · accession 0000950170-23-071929 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-12-20 | 2023-12-19 | XENE | AZAB MOHAMMAD | Dir | M - OptEx | $9.85 | +4,320 | 74.2K | +6% | +$42.6K |
| DM | 2023-12-20 | 2023-12-19 | XENE | AZAB MOHAMMAD | Dir | M - OptEx | $0.00 | -4,320 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2023-12-19 | M | A | 823 | $9.85 | 70,728 | D | — | — | (F1) The common shares issued as a result of the exercise are subject to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023. (F2) The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. |
| 2 | Common | Common Shares | 2023-12-19 | M | A | 3,497 | $9.85 | 74,225 | D | — | — | (F1) The common shares issued as a result of the exercise are subject to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023. (F2) The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. |
| 3 | Derivative | Stock Option (Right to Buy) | 2023-12-19 | M | D | 3,497 | $0.00 | 0 | D | $9.85 · 2016-12-31 to 2024-01-13 | 3,497 Common Shares | (F2) The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. |
| 4 | Derivative | Stock Option (Right to Buy) | 2023-12-19 | M | D | 823 | $0.00 | 0 | D | $9.85 · 2016-12-31 to 2024-01-13 | 823 Common Shares | (F2) The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. |